Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FEMY
stocks logo

FEMY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.14M
+96.02%
-0.090
-60.87%
2.07M
+506.58%
-0.090
-60.87%
2.16M
+427.77%
-0.080
-50%
Estimates Revision
The market is revising Downward the revenue expectations for Femasys Inc. (FEMY) for FY2025, with the revenue forecasts being adjusted by -28.55% over the past three months. During the same period, the stock price has changed by 139.48%.
Revenue Estimates for FY2025
Revise Downward
down Image
-28.55%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.9%
In Past 3 Month
Stock Price
Go Up
up Image
+139.48%
In Past 3 Month
Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.900
sliders
Low
3.00
Averages
5.50
High
8.00
Current: 0.900
sliders
Low
3.00
Averages
5.50
High
8.00
Laidlaw
Yale Jen
initiated
$6.50
2025-11-20
Reason
Laidlaw
Yale Jen
Price Target
$6.50
2025-11-20
initiated
Reason
Laidlaw analyst Yale Jen initiated coverage of Femasys with a Buy rating and $6.50 price target. Femasys is a development stage medical technology company focusing on two lead women healthcare products, FemaSeed and FemBloc, the analyst tells investors in a research note. The firm says FemaSeed is exploring a new and large market opportunity via gynecologist channel while FemBloc is heading to pivotal clinical study backed by "robust" prior clinical data.
JonesResearch
Buy
downgrade
$10 -> $6
2025-05-13
Reason
JonesResearch
Price Target
$10 -> $6
2025-05-13
downgrade
Buy
Reason
JonesResearch lowered the firm's price target on Femasys to $6 from $10 and keeps a Buy rating on the shares. The company reported Q1 earnings with no major updates to catalysts or its cash runway, the analyst tells investors in a research note. The firm remains positive on Femasys, but cut its price target to reflect the delayed launch of FemaSeed and an increase in share count from potential financing in 2025.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$15
2025-03-28
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$15
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$12 → $15
2025-03-19
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12 → $15
2025-03-19
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2025-03-18
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2025-03-18
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2025-03-13
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2025-03-13
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Femasys Inc (FEMY.O) is -2.57, compared to its 5-year average forward P/E of -2.19. For a more detailed relative valuation and DCF analysis to assess Femasys Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.19
Current PE
-2.57
Overvalued PE
-0.55
Undervalued PE
-3.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
14.54
Current PS
0.00
Overvalued PS
33.16
Undervalued PS
-4.08
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

FEMY News & Events

Events Timeline

(ET)
2025-11-25
09:23:02
PharmaCyte divests Femasys shares, anticipates cash reserves increasing to $20M
select
2025-11-10 (ET)
2025-11-10
09:10:50
Femasys Expands International Presence with Second European Order for FemBloc
select
2025-11-03 (ET)
2025-11-03
08:37:21
Femasys receives FDA clearance to proceed with the final phase of FemBloc trial.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
11-25Newsfilter
PharmaCyte Monetizes Femasys Stake, Boosts Cash to $20 Million
  • Enhanced Financial Strength: PharmaCyte successfully monetized its stake in Femasys, with cash and marketable securities expected to rise from $13.3 million to approximately $20 million, significantly improving the company's financial stability and investment capacity.
  • Effective Strategic Execution: CEO Josh Silverman stated that this monetization validates the company's strategic and disciplined capital allocation approach, with plans to continue pursuing value-accretive investment opportunities to enhance shareholder returns.
  • Market Performance Analysis: Despite the improved financial position, PharmaCyte's stock currently trades at $0.65 per share with approximately 6.8 million shares outstanding, indicating a cautious market sentiment regarding its long-term value.
  • Ongoing Investment Strategy: PharmaCyte intends to maintain strict operational management and capital deployment strategies to further enhance shareholder returns while seizing high-quality investment opportunities.
[object Object]
Preview
9.0
10-24NASDAQ.COM
INBX Rises 81% Following Study Results; FEMY, CING, CYH Surge in After-Hours Trading

  • Inhibrx Biosciences Surge: Inhibrx Biosciences (INBX) shares soared over 81% after positive Phase 2 trial results for ozekibart in treating advanced chondrosarcoma, alongside updates on other cancer treatment studies.

  • Femasys Gains: Femasys Inc. (FEMY) saw an 18% increase following the launch of a post-market clinical study for its FemBloc Permanent Birth Control, complying with EU regulations.

  • Cingulate's Presentation: Cingulate Inc. (CING) rose over 6% after announcing that data from its ADHD treatment candidate, CTx-1301, will be presented at the AACAP Annual Meeting, highlighting its potential in ADHD management.

  • Community Health Systems Performance: Community Health Systems, Inc. (CYH) shares increased over 4% after reporting positive Q3 results, contributing to a generally favorable after-hours trading environment for biotech stocks.

[object Object]
Preview
2.0
10-03TipRanks
VTI ETF Update, October 3, 2025

  • VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 0.34% over the past week and 14.7% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting an 11.43% upside.

  • Holdings Analysis: VTI's top five holdings with the highest upside potential include BioAtla and Cibus, while those with the greatest downside risk include Wolfspeed and GoPro; the ETF's Smart Score indicates it may underperform the market.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Femasys Inc (FEMY) stock price today?

The current price of FEMY is 0.9002 USD — it has increased 1.24 % in the last trading day.

arrow icon

What is Femasys Inc (FEMY)'s business?

Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.

arrow icon

What is the price predicton of FEMY Stock?

Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Femasys Inc (FEMY)'s revenue for the last quarter?

Femasys Inc revenue for the last quarter amounts to 729.39K USD, increased 31.44 % YoY.

arrow icon

What is Femasys Inc (FEMY)'s earnings per share (EPS) for the last quarter?

Femasys Inc. EPS for the last quarter amounts to -0.10 USD, decreased -58.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Femasys Inc (FEMY)'s fundamentals?

The market is revising Downward the revenue expectations for Femasys Inc. (FEMY) for FY2025, with the revenue forecasts being adjusted by -28.55% over the past three months. During the same period, the stock price has changed by 139.48%.
arrow icon

How many employees does Femasys Inc (FEMY). have?

Femasys Inc (FEMY) has 69 emplpoyees as of December 05 2025.

arrow icon

What is Femasys Inc (FEMY) market cap?

Today FEMY has the market capitalization of 52.64M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free